The closing price of Viridian Therapeutics Inc (NASDAQ: VRDN) was $18.01 for the day, down -4.10% from the previous closing price of $18.78. In other words, the price has decreased by -$0.77 from its previous closing price. On the day, 849847 shares were traded.
Ratios:
Our analysis of VRDN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 18.26 and its Current Ratio is at 18.26. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On June 14, 2023, BTIG Research started tracking the stock assigning a Buy rating and target price of $46.
On May 30, 2023, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $44.RBC Capital Mkts initiated its Outperform rating on May 30, 2023, with a $44 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 22 ’24 when Fairmount Funds Management LLC bought 476,190 shares for $21.00 per share. The transaction valued at 9,999,990 led to the insider holds 1,839,954 shares of the business.
Meisner Lara sold 27 shares of VRDN for $765 on Jun 16 ’23. The Chief Legal Officer now owns 29,971 shares after completing the transaction at $28.35 per share. On Jun 15 ’23, another insider, Meisner Lara, who serves as the Chief Legal Officer of the company, sold 2,269 shares for $28.02 each. As a result, the insider received 63,577 and left with 29,971 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 1.13B and an Enterprise Value of 881.27M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3646.73 while its Price-to-Book (P/B) ratio in mrq is 4.13. Its current Enterprise Value per Revenue stands at 2.81k whereas that against EBITDA is -3.74.
Stock Price History:
Over the past 52 weeks, VRDN has reached a high of $30.30, while it has fallen to a 52-week low of $10.93. The 50-Day Moving Average of the stock is 19.10, while the 200-Day Moving Average is calculated to be 18.72.
Shares Statistics:
VRDN traded an average of 991.02K shares per day over the past three months and 1.36M shares per day over the past ten days. A total of 62.77M shares are outstanding, with a floating share count of 55.85M. Insiders hold about 11.02% of the company’s shares, while institutions hold 90.43% stake in the company. Shares short for VRDN as of Feb 29, 2024 were 7.57M with a Short Ratio of 7.64, compared to 8.42M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 12.07% and a Short% of Float of 12.34%.
Earnings Estimates
The firm’s stock currently is rated by 12 analysts. On average, analysts expect EPS of -$1.1 for the current quarter, with a high estimate of -$0.81 and a low estimate of -$1.36, while EPS last year was -$1.61. The consensus estimate for the next quarter is -$1.11, with high estimates of -$0.84 and low estimates of -$1.34.
Analysts are recommending an EPS of between -$3.44 and -$5.72 for the fiscal current year, implying an average EPS of -$4.54. EPS for the following year is -$4.57, with 12 analysts recommending between -$3.23 and -$6.69.
